Home

Our Mission

At Cycuria, we are dedicated to developing novel cytokine-based therapies to dramatically improve outcomes for patients with hematological cancers and other hard-to-treat solid cancers, offering hope where traditional treatments have fallen short.

Explore our science

Our Team

Our experienced management team brings deep expertise in cytokine biology, protein engineering, and hematologic oncology drug development, with a focus on developing therapies that directly target cancer cells.

Explore our team

Your Career

Join our mission to transform blood cancer treatment with our groundbreaking approach. We offer exciting opportunities for talented scientists and drug developers to make a significant impact in the field of oncology ...

Explore your career

Previous slide

Next slide

The Current Gap

Acute Myeloid Leukemia (AML) remains a challenging disease with poor long-term outcomes despite significant advancements in treatment.

While new therapies, such as FLT3 inhibitors and venetoclax-based regimens, have improved initial response rates, durable remissions and long-term survival remain elusive, particularly for older or unfit patients who cannot tolerate intensive chemotherapy or stem cell transplants ...

Our Breakthrough approach

Cycuria Therapeutics is revolutionizing blood cancer treatment with its proprietary engineered cytokines.

Our approach directly and specifically targets leukemic cells and their progenitor stem cells, while preserving healthy blood formation and minimizing systemic toxicity...

High incidence rate for AML,
specially in >60 yrs population

in every 100.000

Poor Overall survival rate
for AML patients

0 %

3-year survival rate

TEAM

Our experienced management team brings deep expertise in cytokine biology, protein engineering, clinical hemato-oncology and early-stage drug discovery and development

Our Blog

Latest CYCURIA News

Event Participitation

Meet Cycuria at ASH Annual Meeting 2024 in San Diego

Cycuria will be attending the upcoming American Society of Hematology (ASH) Annual Meeting in San Diego from December 7- December 10. We look forward to

Dezember 3, 2024

News & Press releases

Cycuria Founder, Prof. Dr. Philipp Jost, Highlights the Strategic Advantages and Opportunities at Medical Science City Graz

We’re thrilled to share recent press coverage highlighting Cycuria Therapeutics‘ innovative approach in oncology and our choice to establish roots in Graz’s Medical Science City,

November 7, 2024

News & Press releases

Cycuria Featured in the Austrian National Newspaper Die Presse

Die Presse, one of Austria’s most respected national newspapers, features our scientific breakthrough in cancer research led by our scientific founder, Prof. Dr. Philipp Jost.

Oktober 22, 2024